Sarepta Therapeutics
SRPT
269 hedge funds and large institutions have $4.2B invested in Sarepta Therapeutics in 2018 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 76 increasing their positions, 110 reducing their positions, and 35 closing their positions.
78% more call options, than puts
Call options by funds: $198M | Put options by funds: $111M
51% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 35
39% more capital invested
Capital invested by funds: $3.03B → $4.2B (+$1.17B)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
6% more funds holding
Funds holding: 254 → 269 (+15)
1.9% more ownership
Funds ownership: 85.46% → 87.36% (+1.9%)
31% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 110
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$279M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$102M |
| 3 |
RI
RTW Investments
New York
|
+$45.9M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$34.4M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$30.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$72.9M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$58.1M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$57.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38.7M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$32.2M |
SRPT Hedge Fund Activity: Q1 2018 in Review
269 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2018, worth a combined $4.2B — up 39% from $3.03B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new SRPT positions and 35 closed out — a net gain of 18 holders — while 76 added to existing stakes and 110 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $279M. The largest seller was HealthCor Management, exiting entirely with an estimated $72.9M sold.
- 269 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2018, up from 254 in Q4 2017.
- Funds reported $4.2B of Sarepta Therapeutics stock for Q1 2018, up 39% quarter-over-quarter.
- 53 funds opened new Sarepta Therapeutics positions in Q1 2018 and 35 closed out, a net change of +18 holders.
- The largest Sarepta Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $279M added.
- The largest Sarepta Therapeutics seller in Q1 2018 was HealthCor Management, an estimated $72.9M sold.
Based on aggregated 13F filings for Q1 2018.